Minnesota med school weighing gift and grants ban

Share this article:
The University of Minnesota Medical School is weighing a tough ban on gifts to physicians and requiring docs to publicly disclose all relationships with drug companies, according to a University newspaper.

Those measures are included in the recommendations of a University Medical School conflict-of-interest task force, which also called for: limiting the use of pharmaceutical samples and centralizing their distribution; curbing and ultimately eliminating industry funding for education; eliminating the $10,000 threshold defining a “significant financial interest” and requiring instead that all financial involvement be reported; registering clinical trials; a ban on ghostwriting and new disclosure requirements for publication of articles by university employees. In addition, under the task force plan, conflict-of-interest policies would be extended to non-human research, students and short-term faculty or those on leave.

Instructors would be required to disclose relationships with drug companies to students, and doctors would be required to disclose industry ties directly to patients and online, through a university-administered website.

In its executive summary, the task force acknowledged the value of some interactions with industry in research, care and education, but said “both real and perceived conflicts of interest between health professionals' financial interests and the best interests of patients can damage the image of the profession and the medical school.”

The Minnesota Daily noted that the American Medical Student Association recently graded the University Medical School a ‘D' for weak conflict-of-interest policies.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.